Skip to main content
. 2017 Aug 21;44(3):560–574. doi: 10.1093/schbul/sbx109

Table 1.

Demographic Characteristics of the Sample

CIQ (n = 47) DIQ (n = 100) PIQ (n = 73) HC (n = 168) Comparisons
Gender (% male) 74 69 74 48 χ2(3) = 23.06, P < .001
Diagnostic distribution (% SZ) 82 86 81 χ2(2) = 0.53, P = .77
Medications (% using)
 Anticholinergic 13 8 1 χ2(2) = 6.25, P = .04
 Anticonvulsant 11 18 12 χ2(2) = 1.83, P = .40
 Antidepressant 32 35 33 χ2(2) = 0.17, P = .92
 Atypical antipsychotics 85 81 84 χ2(2) = 0.43, P = .81
 Typical antipsychotics 13 7 11 χ2(2) = 1.50, P = .48
 Anxiolytic 9 20 3 χ2(2) = 12.69, P = .002
 Lithium 2 8 0 χ2(2) = 7.47, P = .02
M (SD) M (SD) M (SD) M (SD) Comparisons Post hoc comparisons a
Age 37.30 (8.45) 36.05 (9.33) 40.06 (10.97) 39.74 (13.74) F(3, 384) = 2.88, P = .036 PIQ > DIQ; DIQ < HC
Illness duration 13.59 (9.85) 13.31 (7.71) 16.25 (10.54) - F(2, 217) = 2.64, P = .074 PIQ > DIQ
Positive symptoms—current 2.29 (2.93) 1.88 (2.56) 1.30 (2.38) F(2, 189) = 2.08, P = .13 -
Negative symptoms 35.00 (20.53) 24.55 (17.18) 22.66 (14.87) F(2, 205) = 7.89, P < .001 CIQ > DIQ and PIQ
GAF 44.68 (11.79) 55.13 (11.33) 56.39 (12.50) 84.48 (9.46) F(3, 354) = 242.48, P < .001 CIQ < DIQ = PIQ < HC

Note: CIQ, compromised patients; DIQ, deteriorated patients; PIQ, putatively preserved patients.

aSignificant at P < .05.